Mary Alikian

BCR-ABL1 compound mutations in tyrosine kinase inhibitor–resistant CML: frequency and clonal relationships

Jamshid S. Khorashad, Todd W. Kelley, Philippe Szankasi et al. · Blood · 2012 · 223 citations

Medicine, Molecular Biology, Oncology +14

A Novel Pyrazolo[1,5-<i>a</i>]pyrimidine Is a Potent Inhibitor of Cyclin-Dependent Protein Kinases 1, 2, and 9, Which Demonstrates Antitumor Effects in Human Tumor Xenografts Following Oral Administration

Dean A. Heathcote, Hetal Patel, Sebastian H. B. Kroll et al. · Journal of Medicinal Chemistry · 2010 · 103 citations · Full text

Medicine, Oncology, Pharmacology +15

Mutational landscape of B‐cell post‐transplant lymphoproliferative disorders

Thomas Menter, Darius Juškevičius, Mary Alikian et al. · British Journal of Haematology · 2017 · 83 citations · Full text

Medicine, Hematology, Oncology +16

RT-qPCR and RT-Digital PCR: A Comparison of Different Platforms for the Evaluation of Residual Disease in Chronic Myeloid Leukemia

Mary Alikian, Alexandra S. Whale, Susanna Akiki et al. · Clinical Chemistry · 2016 · 75 citations

Medicine, Hematology, Oncology +16

Identification and validation of a novel pathogenic variant in <scp><i>GDF2</i></scp> (<scp>BMP9</scp>) responsible for hereditary hemorrhagic telangiectasia and pulmonary arteriovenous malformations

Srimmitha Balachandar, Tamara Graves, Anika Shimonty et al. · American Journal of Medical Genetics Part A · 2021 · 60 citations · Full text

Life Sciences, Genetics, Molecular Genetics +16